5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
Anticancer Res
; 20(4): 2457-62, 2000.
Article
in En
| MEDLINE
| ID: mdl-10953310
ABSTRACT
BACKGROUND:
Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme of 5-fluorouracil (5-FU) catabolism. Several studies have demonstrated the clinical importance of DPD in cancer patients, suggesting that the efficacy of 5-FU may be related to DPD activity in tumor tissue. In the present study, DPD activity and chemosensitivity to 5-FU were evaluated in advanced gastric cancer. MATERIALS ANDMETHODS:
Thirty-four gastric cancers from 32 patients were studied and chemosensitivity to 5-FU was evaluated by histoculture drug response assay. RESULTS ANDCONCLUSION:
DPD activity and tumor inhibition of 5-FU among all cases showed no significant correlation, but among 14 histologically differentiated cases significant correlation was observed. DPD activity may be useful in determining the 5-FU sensitivity of differentiated gastric cancer.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oxidoreductases
/
Stomach Neoplasms
/
Fluorouracil
/
Antimetabolites, Antineoplastic
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
Anticancer Res
Year:
2000
Type:
Article
Affiliation country:
Japan